Ghent University Academic Bibliography

Advanced

Statins, systemic inflammation and risk of death in COPD: the Rotterdam Study

Lies Lahousse UGent, Daan W Loth, Guy Joos UGent, Albert Hofman, Hubert GM Leufkens, Guy Brusselle UGent and Bruno H Stricker (2013) PULMONARY PHARMACOLOGY & THERAPEUTICS. 26(2). p.212-217
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
statin, Chronic obstructive pulmonary disease (COPD), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor, Creactive protein (CRP), inflammation, systemic, mortality, OBSTRUCTIVE PULMONARY-DISEASE, C-REACTIVE PROTEIN, CARDIOVASCULAR-DISEASE, MORTALITY, CHOLESTEROL, COMORBIDITIES, ASSOCIATION, PREVENTION, EMPHYSEMA, SURVIVAL
journal title
PULMONARY PHARMACOLOGY & THERAPEUTICS
Pulm. Pharmacol. Ther.
volume
26
issue
2
pages
212 - 217
Web of Science type
Article
Web of Science id
000317149100008
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
2.57 (2013)
JCR rank
108/256 (2013)
JCR quartile
2 (2013)
ISSN
1094-5539
DOI
10.1016/j.pupt.2012.10.008
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
3067205
handle
http://hdl.handle.net/1854/LU-3067205
date created
2012-12-07 08:22:44
date last changed
2014-11-21 12:51:57
@article{3067205,
  author       = {Lahousse, Lies and Loth, Daan W and Joos, Guy and Hofman, Albert and Leufkens, Hubert GM and Brusselle, Guy and Stricker, Bruno H},
  issn         = {1094-5539},
  journal      = {PULMONARY PHARMACOLOGY \& THERAPEUTICS},
  keyword      = {statin,Chronic obstructive pulmonary disease (COPD),3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor,Creactive protein (CRP),inflammation,systemic,mortality,OBSTRUCTIVE PULMONARY-DISEASE,C-REACTIVE PROTEIN,CARDIOVASCULAR-DISEASE,MORTALITY,CHOLESTEROL,COMORBIDITIES,ASSOCIATION,PREVENTION,EMPHYSEMA,SURVIVAL},
  language     = {eng},
  number       = {2},
  pages        = {212--217},
  title        = {Statins, systemic inflammation and risk of death in COPD: the Rotterdam Study},
  url          = {http://dx.doi.org/10.1016/j.pupt.2012.10.008},
  volume       = {26},
  year         = {2013},
}

Chicago
Lahousse, Lies, Daan W Loth, Guy Joos, Albert Hofman, Hubert GM Leufkens, Guy Brusselle, and Bruno H Stricker. 2013. “Statins, Systemic Inflammation and Risk of Death in COPD: The Rotterdam Study.” Pulmonary Pharmacology & Therapeutics 26 (2): 212–217.
APA
Lahousse, L., Loth, D. W., Joos, G., Hofman, A., Leufkens, H. G., Brusselle, G., & Stricker, B. H. (2013). Statins, systemic inflammation and risk of death in COPD: the Rotterdam Study. PULMONARY PHARMACOLOGY & THERAPEUTICS, 26(2), 212–217.
Vancouver
1.
Lahousse L, Loth DW, Joos G, Hofman A, Leufkens HG, Brusselle G, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam Study. PULMONARY PHARMACOLOGY & THERAPEUTICS. 2013;26(2):212–7.
MLA
Lahousse, Lies, Daan W Loth, Guy Joos, et al. “Statins, Systemic Inflammation and Risk of Death in COPD: The Rotterdam Study.” PULMONARY PHARMACOLOGY & THERAPEUTICS 26.2 (2013): 212–217. Print.